Home » Stocks » FLXN

Flexion Therapeutics, Inc. (FLXN)

Stock Price: $11.46 USD 0.14 (1.24%)
Updated December 4, 4:00 PM EST - Market closed

FLXN Stock Price Chart

Key Info

Market Cap 565.15M
Revenue (ttm) 82.90M
Net Income (ttm) -127.58M
Shares Out 49.30M
EPS (ttm) -3.02
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day December 4
Last Price $11.46
Previous Close $11.32
Change ($) 0.14
Change (%) 1.24%
Day's Open 11.36
Day's Range 11.23 - 11.56
Day's Volume 192,391
52-Week Range 5.53 - 21.13

FLXN Stock News

GlobeNewsWire - 1 month ago

Company to hold conference call today at 8:30 a.m. ET Company to hold conference call today at 8:30 a.m. ET

GlobeNewsWire - 1 month ago

BURLINGTON, Mass., Oct. 08, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that Adam Muzikant, Ph.D., Senior Vice President, Business Development, will prese...

GlobeNewsWire - 2 months ago

BURLINGTON, Mass., Oct. 02, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced equity inducement grants to two new employees consisting of 3,315 restricted stock...

GlobeNewsWire - 2 months ago

BURLINGTON, Mass., Sept. 09, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that Michael Clayman, M.D., President and Chief Executive Officer, will partici...

GlobeNewsWire - 2 months ago

BURLINGTON, Mass., Sept. 08, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced the treatment of the first patient in the second cohort of the Phase 1 dose-esc...

GlobeNewsWire - 3 months ago

BURLINGTON, Mass., Sept. 03, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that Michael Clayman, M.D., President and Chief Executive Officer, will partici...

GlobeNewsWire - 3 months ago

BURLINGTON, Mass., Aug. 19, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced the appointment of Elizabeth (Liz) Kwo, MD, Staff Vice President, Clinical Data ...

Zacks Investment Research - 3 months ago

Flexion Therapeutics (FLXN) delivered earnings and revenue surprises of -8.57% and -0.07%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the s...

GlobeNewsWire - 3 months ago

BURLINGTON, Mass., Aug. 05, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today reported financial results and recent business highlights for the quarter ended June 30, 2...

Investors Business Daily - 4 months ago

A Relative Strength Rating upgrade for Flexion Therapeutics shows improving technical performance. Will it continue?

GlobeNewsWire - 4 months ago

BURLINGTON, Mass., July 30, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that it will report its second-quarter 2020 financial results and recent busines...

Zacks Investment Research - 4 months ago

Flexion Therapeutics (FLXN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

InvestorPlace - 4 months ago

FLXN stock has been falling because the company is not in the race for a Covid-19 vaccine. But as that field narrows, FLX is worth a look.

Zacks Investment Research - 4 months ago

Does Flexion Therapeutics (FLXN) have what it takes to be a top stock pick for momentum investors? Let's find out.

Zacks Investment Research - 4 months ago

Investors need to pay close attention to Flexion (FLXN) stock based on the movements in the options market lately.

GlobeNewsWire - 4 months ago

BURLINGTON, Mass., July 14, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced preliminary ZILRETTA net sales of $15.4 million for the quarter ended June 30, 2...

Zacks Investment Research - 4 months ago

Flexion Therapeutics (FLXN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

GlobeNewsWire - 5 months ago

BURLINGTON, Mass., June 16, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that Michael Clayman, M.D., President and Chief Executive Officer, will particip...

Zacks Investment Research - 6 months ago

Flexion (FLXN) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.

Seeking Alpha - 6 months ago

Planning For A Rebound In Flexion Therapeutics

The Motley Fool - 6 months ago

The company priced a share offering, diluting existing shareholders.

GlobeNewsWire - 6 months ago

BURLINGTON, Mass., May 21, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced the pricing of an underwritten public offering of 9,230,770 shares of its common ...

GlobeNewsWire - 6 months ago

BURLINGTON, Mass., May 20, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that it has commenced an underwritten public offering of $75,000,000 of shares of...

Zacks Investment Research - 6 months ago

Flexion Therapeutics (FLXN) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Seeking Alpha - 6 months ago

Flexion Therapeutics' (FLXN) CEO Michael Clayman on Q1 2020 Results - Earnings Call Transcript

GlobeNewsWire - 7 months ago

BURLINGTON, Mass., May 01, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced the publication of data from two new analyses of patients treated with ZILRETTA (...

GlobeNewsWire - 7 months ago

BURLINGTON, Mass., April 27, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced new positive preclinical efficacy and pharmacokinetic (PK) data for FX301, its ...

24/7 Wall Street - 7 months ago

Every time there is major carnage in the stock market, you see top companies trade into the single digits.

Other stocks mentioned: EVRI, HAL, LADR, NOK
GlobeNewsWire - 8 months ago

BURLINGTON, Mass., April 01, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that it has entered into an exclusive license agreement with HK Tainuo and Jian...

Seeking Alpha - 8 months ago

Flexion reported positive Q4/2019 earnings in the midst of the Coronavirus Crash. The stock has taken a nosedive to all-time lows and I am looking to take advantage.

Seeking Alpha - 8 months ago

Flexion Therapeutics, Inc. (FLXN) CEO Mike Clayman on Q4 2019 Results - Earnings Call Transcript

Zacks Investment Research - 8 months ago

Flexion Therapeutics (FLXN) delivered earnings and revenue surprises of 12.87% and 0.65%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for th...

GlobeNewsWire - 8 months ago

BURLINGTON, Mass., March 11, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that Melissa Layman has been named Chief Commercial Officer (CCO). Ms. Layman j...

GlobeNewsWire - 8 months ago

BURLINGTON, Mass., March 06, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced equity inducement grants to three new employees consisting of an aggregate of 8...

Zacks Investment Research - 8 months ago

Flexion Therapeutics (FLXN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research - 9 months ago

Flexion Therapeutics (FLXN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

GlobeNewsWire - 9 months ago

BURLINGTON, Mass., Feb. 07, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced equity inducement grants to 13 new employees consisting of an aggregate of 40,50...

Seeking Alpha - 10 months ago

Flexion Therapeutics: A Good Foundation For Growth In 2020

GlobeNewsWire - 10 months ago

BURLINGTON, Mass., Jan. 09, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced preliminary and unaudited revenue for the fourth-quarter and full-year ended Dec...

GlobeNewsWire - 11 months ago

BURLINGTON, Mass., Jan. 03, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced equity inducement grants to five new employees consisting of an aggregate of 17,...

Zacks Investment Research - 11 months ago

Investors need to pay close attention to Flexion (FLXN) stock based on the movements in the options market lately.

Zacks Investment Research - 11 months ago

Flexion's (FLXN) sNDA for osteoarthritis drug, Zilretta, seeking removal of confusing limitation of use label, gets FDA approval.

Seeking Alpha - 11 months ago

Flexion Therapeutics continues to benefit as the ramp up of its primary product Zilretta progresses at a rapid clip.

Seeking Alpha - 11 months ago

Flexion: Sweet Clarity

The Motley Fool - 11 months ago

A key FDA decision could pave the way for higher sales of the company's flagship drug.

Benzinga - 11 months ago

Flexion Therapeutics Inc (NASDAQ: FLXN) shares are on a tear after the FDA approved an update this week of the product label for its osteoarthritis pain drug Zilretta, which was originally app...

24/7 Wall Street - 11 months ago

Flexion Therapeutics Inc. (NASDAQ: FLXN) shares popped on Friday after the company announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental New Drug Application (...

Market Watch - 11 months ago

Shares of Flexion Therapeutics Inc. FLXN, -0.08% soared more than 24% in premarket trade Friday, after the company said the U.S.

GlobeNewsWire - 11 months ago

BURLINGTON, Mass., Dec. 26, 2019 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental New...

GlobeNewsWire - 11 months ago

BURLINGTON, Mass., Dec. 17, 2019 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that the first three patients were enrolled in a clinical trial to evaluate the ...

About FLXN

Flexion Therapeutics, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for the treatment of patients with musculoskeletal conditions. It offers ZILRETTA, an intra-articular injection for the management of osteoarthritis (OA) pain of the knee in the United States. The company also develops FX201, a gene therapy product candidate designed to stimulate the production of an anti-inflammatory protein, interleukin-1 receptor antagonist for pain relief from OA of the knee; and FX301, an administere... [Read more...]

Industry
Drug Manufacturers-Specialty & Generic
IPO Date
Feb 12, 2014
CEO
Michael Clayman
Employees
288
Stock Exchange
NASDAQ
Ticker Symbol
FLXN
Full Company Profile

Financial Performance

In 2019, FLXN's revenue was $72.96 million, an increase of 223.91% compared to the previous year's $22.52 million. Losses were -$149.77 million, -11.72% less than in 2018.

Financial Statements

Analyst Forecasts

The average 12-month stock price forecast for FLXN is 20.25, which is an increase of 76.70% from the latest price.

Price Target
$20.25
(76.70% upside)